04/2023
Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Clinical Cancer Research
Read More
02/2023
Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development
HCC-TAG
Read More
01/2023
Denifanstat (DEN), a first-in-class fatty acid synthase (FASN) inhibitor, significantly reduces plasma tripalmitin, a marker of de novo lipogenesis, in NASH patients in the FASCINATE-1 and FASCINATE-2 clinical studies
NASH-TAG
Read More
01/2023
Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients
NASH-TAG
Read More
11/2022
Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe Non-alcoholic Steatohepatitis (NASH) Patients
Denifanstat Showed Statistically Significant Improvements Across Key Disease Markers in FASCINATE-2 Study After 26 Weeks of Treatment Highlights to be Included in Oral Presentation Session at The Liver Meeting on…
Read More
11/2022
Correlation between AI-based digital pathology and non-invasive tests (NITs) – baseline data from the FASCINATE-2 phase 2b clinical study of denifanstat in patients with F2/F3 NASH
AASLD The Liver Meeting
Read More
11/2022
A baseline metabolomic signature predicts liver fat (MRI-PDFF) response for denifanstat, a first-in-class, fatty acid synthase (FASN) inhibitor: analysis in FASCINATE-1 and FASCINATE-2 clinical studies
AASLD The Liver Meeting
Read More
11/2022
Serum proteomic profiling reveals that the fatty acid synthase (FASN) inhibitor denifanstat provides metabolic benefits via increasing fibroblast growth factor 19 (FGF19) and decreasing 3-hydroxy-3-methylglutaryl-coa synthase 1 (HMGCS1) in NASH patients
AASLD The Liver Meeting
Read More
10/2022
Sagimet Biosciences Announces Late-Breaking, Oral and Poster Presentations for Denifanstat (TVB-2640), a First-in-Class Fatty Acid Synthase Inhibitor, in NASH at AASLD’s The Liver Meeting
Additional Preclinical Data on Denifanstat Published in Scientific Reports San Mateo, California, October 31, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today…
Read More
10/2022
Sagimet Biosciences Announces Appointment of David Happel to Chief Executive Officer; Dr. George Kemble to Transition to Executive Chairman Role
San Mateo, California, October 24, 2022 – Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced today that it has appointed David Happel as chief…
Read More